Casdatifan (Cas) monotherapy in patients (pts) with previously treated clear cell renal cell carcinoma (ccRCC): Safety, efficacy and subgroup analysis across multiple doses from ARC-20, a phase 1 open ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback